Application 022124
- Type
- NDA
- Sponsor
- NYCOMED US INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | OMNARIS | CICLESONIDE | SPRAY; NASAL | 50MCG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Alvesco | CICLESONIDE | Covis Pharma US, Inc | 9f6112fb-78ef-43cf-8ae3-36370eb45468 | 2025-02-28 | Warnings, Adverse reactions | CICLESONIDE |
| Omnaris | CICLESONIDE | Covis Pharma US, Inc | 15fefd46-ac7e-40d0-b635-e6c3d653c666 | 2022-11-08 | Warnings, Adverse reactions | Omnaris CICLESONIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.